Hyderabad-based IIL gets DCGI’s, State admin’s approval to manufacture MR vaccine

| | New Delhi
  • 0

Hyderabad-based IIL gets DCGI’s, State admin’s approval to manufacture MR vaccine

Tuesday, 28 March 2023 | Pioneer News Service | New Delhi

Hyderabad-based Indian Immunologicals Limited (IIL), a vaccine manufacturer has announced receipt of approval from Drugs Controller General of India (DCGI) and State Drug Control Administration for manufacture of Measles-Rubella (MR) Vaccine.

This is the outcome of the Indo-Vietnam partnership, where IIL partnered with the Center for Research and Production of Vaccines and Biologicals, also called Polyvac, Vietnam.

Under an exclusive agreement, Polyvac, Vietnam will supply the Measles vaccine component to IIL. Rubella Vaccine components will be produced by IIL to manufacture a combined MR vaccine. This Live Attenuated MR vaccine adds to the list of several other vaccines that IIL supplies to Universal Immunization Programme (UIP) of India. This vaccine has been proven through extensive human clinical trials to be immunogenic and safe for people of 9 months to 49 years.

Dr K Anand Kumar, Managing Director, IIL said, “We have successfully completed all phases of Product development to the satisfaction of the regulatory authorities in India. Measles-Rubella (MR) vaccine is listed in the UIP of India and is an important vaccine for our country. IIL’s collaborative effort will help in the immunization of several million children against Measles and Rubella and thereby saving lives’ ‘.

Sunday Edition

Hidden Gem in the Wilderness

26 November 2023 | Advaita Kala | Agenda

SUPERBUGS ON PROWL

26 November 2023 | Archana Jyoti | Agenda

AI in skincare: a game changer

26 November 2023 | Meera Iyer | Agenda

Soaring childhood myopia a cause of concern

26 November 2023 | Dr Mahipal Singh Sachdev | Agenda

Astroturf | Address negatives to come out with your best

26 November 2023 | Bharat Bhushan Padmadeo | Agenda

Fate & fortune of blue eyed boy Vivek Ramaswamy

26 November 2023 | Manan Dwivedi | Agenda